|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C7H9NO2 |
|||
| Molecular Weight | 139.15 | CAS No. | 30652-11-0 | |
| Solubility (25°C)* | In vitro | Water | 28 mg/mL (201.22 mM) | |
| DMSO | Insoluble | |||
| Ethanol | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | Deferiprone (CP20) is a chelating agent with an affinity for ferric ion (iron III)，binds with ferric ions to form neutral 3:1 (deferiprone:iron) complexes that are stable over a wide range of pH values. |
|---|---|
| In vitro | Deferiprone (100 μM) is able to protect myocytes from doxorubicin-induced lactate dehydrogenase release. Deferiprone (300 μM) quickly and efficiently removes iron(III) from its complex with doxorubicin. Deferiprone (300 μM) rapidly enters myocytes and displaces iron from a fluorescence-quenched trapped intracellular iron-calcein complex, suggesting that in the myocyte, deferiprone should also be able to displace iron from its complex with doxorubicin. Deferiprone (3 mM) also greatly reduces hydroxyl radical production by the iron(III)-doxorubicin complex in the xanthine oxidase/xanthine superoxide generating system. [1] Deferiprone (0.5 mM) increases removal of RBC membrane free iron in a time and dose dependent manner. [2] Deferiprone (0.3 mM) is effective in inhibiting radioactive iron mobilization from iron-loaded heart cells and protecting or restoring mitochondrial respiratory enzyme activity. Deferiprone (1 mM) results in a sharp decrease in complex I-III activity in iron-loaded heart cells. [3] Deferiprone shows cytotoxic effect of human tumor cell lines HSC-2, HSC-3 and HL-60 with IC50 of 13.5 μg/mL, 9.9 μg/mL and 10.6 μg/mL, the cytotoxic activity of HK1 against HL-60 and HSC-2 cells is reduced in the presence of FeCl3. Deferiprone (100 μg/mL) induces internucleosomal DNA fragmentation in HL-60 cells, but the addition of FeCl3 inhibits the DNA fragmentation. Deferiprone (100 μg/mL) activates the caspase 3, 8 and 9 in HSC-2 cells. [4] |
| In vivo | Deferiprone (100 mg/kg) reduces the mean basilar artery cross-sectional areas by 24% in rabbits. Deferiprone (100 mg/kg) combined with subarachnoid hemorrhage(SAH) shows a variable amount of corrugation of the internal elastic lamina in rabbits. [5] |
| Features | Possesses 10-fold higher cytotoxicity than maltol in both HL-60 and HSC-2 cell lines. |
Protocol (from reference)
References
Selleck's Deferiprone has been cited by 14 publications
| Irradiated tumour cell-derived microparticles upregulate MHC-I expression in cancer cells via DNA double-strand break repair pathway [ Cancer Lett, 2024, 592:216898] | PubMed: 38670306 |
| Sevoflurane Exposure Induces Neuronal Cell Ferroptosis Initiated by Increase of Intracellular Hydrogen Peroxide in the Developing Brain via ER Stress ATF3 Activation [ Mol Neurobiol, 2024, 61(4):2313-2335] | PubMed: 37874483 |
| Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer [ Cell Death Dis, 2023, 14(8):532] | PubMed: 37596261 |
| Selective ablation of primary and paracrine senescent cells by targeting iron dyshomeostasis [ Cell Rep, 2023, 42(2):112058] | PubMed: 36753419 |
| The Effect of 4-Methylcatechol on Platelets in Familial Hypercholesterolemic Patients Treated with Lipid Apheresis and/or Proprotein Convertase Subtilisin Kexin 9 Monoclonal Antibodies [ Nutrients, 2023, 15(8)1842] | PubMed: 37111061 |
| Effects of Supplemental Drugs on Hexaminolevulinate (HAL)-Induced PpIX Fluorescence in Bladder Cancer Cell Suspensions [ Int J Mol Sci, 2022, 23(14)7631] | PubMed: 35886979 |
| Iron contributes to photoreceptor degeneration and Müller glia proliferation in the zebrafish light-treated retina [ Exp Eye Res, 2022, 216:108947] | PubMed: 35074344 |
| Shuganning injection, a traditional Chinese patent medicine, induces ferroptosis and suppresses tumor growth in triple-negative breast cancer cells [ Phytomedicine, 2021, 85:153551] | PubMed: 33827043 |
| Berberine alleviates liver fibrosis through inducing ferrous redox to activate ROS-mediated hepatic stellate cells ferroptosis [ Cell Death Discov, 2021, 7(1):374] | PubMed: 34864819 |
| Iron chelators inhibit amyloid-β-induced production of lipocalin 2 in cultured astrocytes. [ Neurochem Int, 2020, 132:104607] | PubMed: 31760034 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.